Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjects with a recent history of acute myocardial infarction.
ACTIVE ENROLLING SIGN UP
SPONSOR: Idorsia Pharmaceuticals, Ltd
1. Male or female subject ≥ 18 years old
2. Discharged with a confirmed diagnosis of symptomatic type 1 AMI (STEMI or NSTEMI), no longer than 4 weeks prior to randomization